Preview Newsletter
XARELTO Media Monitoring – Week of 12-18-15
-
Xarelto Lawsuit Alleges Drug Caused Fatal Bleed And Death Of Grandmother
Dec 11, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against blood thinner Xarelto and manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). This particular lawsuit was filed by a granddaughter on behalf of her grandmother who passed away while using Xarelto. She was prescribed the drug in September 0f 2014 in order to treat her deep vein thrombosis condition. Just two months later, she suffered from an intracranial bleed. The bleed quickly became what the plaintiff refers to as “irreversible and fatal,” and the grandmother ultimately passed away on November 14th of 2014, just two months after starting to use the blood thinner. -
Xarelto Lawsuit Plaintiff From NJ Alleges Drug Cause Severe And Permanent Injuries
Dec 12, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a new lawsuit filed by a man from New Jersey alleging that Janssen Pharmaceuticals (a division of Johnson & Johnson) neglected to properly warn consumers about the severe health risks and dangerous side effects associated with its blood-thinning drug Xarelto. The lawsuit was filed on November 23rd of 2015 in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06264. -
Xarelto Lawsuit Plaintiffs From Nebraska Allege Drug Caused Severe And Permanent Side Effects
Dec 15, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinner Xarelto and manufacturer Janssen Pharmaceuticals, (a division of Johnson & Johnson). The plaintiffs in this case are a couple from Nebraska who allege that the manufacturer marketed an unsafe drug which caused the husband severe and permanent side effects including bleeding and shortened life expectancy. -
Xarelto Wrongful Death Lawsuit Filed In South Florida Sues For Uncontrollable Fatal Bleeding
Dec 16, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a new lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) claiming wrongful death. The suit was filed in south Florida and claims that Xarelto manufacturers failed to properly warn consumers of the significant dangers associated with their blood-thinning drug. The plaintiff alleges that the drug caused her husband to die after suffering an episode of uncontrollable internal bleeding. -
Lawsuitsettlementnews.com Secures Large Capital for Xarelto and Pradaxa Funding
Dec 16, 2015 | LawsuitSettlements.com
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they have secured large capital for Xarelto and Pradaxa funding. They are also reporting that they are able to provide assistance for Xarelto and Pradaxa bleeding victims, or their loved ones, who are in need of an attorney. Pradaxa and Xarelto are both blood thinners and targets of thousands of lawsuit claims, with similar allegations of uncontrollable and sometimes fatal bleeding events. -
Xarelto Lawsuit Alleges Studies On Blood Thinner Were Not Reliable Or Properly Managed
Dec 17, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed against the manufacturers of blood-thinning drug Xarelto, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The lawsuit alleges that the companies neglected to properly warn consumers of the significant bleeding issues associated with their drug, and also that the studies that medical journals and advertisements relied on were unreliable and improperly managed. The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-04273. -
Xarelto Lawsuit Plaintiff Alleges That Manufacturers' Negligence Caused Husband's Death
Dec 18, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed which details the dangerous side effects associated with anticoagulant Xarelto. This lawsuit now joins with others consolidated in MDL number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. The MDL is being overseen in the U.S. District Court for the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. -
Xarelto Lawsuit Alleges Life-Threatening Severe Bleeding Event
Dec 11, 2015 | Top Class Actions
By Laura Schultz
A Xarelto lawsuit claims that after five-months of use, the drug caused an Ohio man to suffer from a life-threatening rectal bleed. -
Six Years for Troubled Xarelto v. Six Decades for Reliable Coumadin
Dec 14, 2015 | LawyersandSettlements.com
By Gordon Gibb
As we are about a month away from the selection of four bellwether Xarelto trials that are scheduled for early 2017, it’s instructive to compare the rocky road of Xarelto with the longevity of Coumadin (warfarin). The latter had been the gold standard for blood thinning well before the introduction of Xarelto and, before that, Pradaxa. In the short tenure of Xarelto as the currently leading anticoagulant, more than 1,700 plaintiffs have reported a Xarelto Bleeding Issue. -
Several Claims Added to Xarelto MDL
Dec 12, 2015 | Drug Reporter
By Stephanie Reid
On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known rivaroxaban, is a relatively new blood thinning drug touted to offer patients an increased level of convenience as they treat their underlying medical conditions. -
Xarelto MDL: Drug Makers Attempt Geographic Limitations
Dec 14, 2015 | Top Class Actions
By Amanda Antell
Pharmaceutical giants Bayer and Janssen have been accused of trying to undermine the Xarelto bellwether litigation process by limiting early trial candidates to only a handful of states. -
Xarelto Internal Bleeding Injuries Lawsuit Filed In Mississippi
Dec 15, 2015 | BloodThinnerHelp.com
By Joseph Osborne
Xarelto is a highly popular blood thinner drug that has seen over 11 million scripts written in all of America. Xarelto is prescribed in order to avert blood clots forming that can lead to severe strokes. However, Xarelto has been closely examined by the medical community in an effort to determine theside effects this anticoagulant could have. The research conducted over Xarelto usage has associated the drug to serious side effects like uncontrollable internal bleeding. There have already beenlawsuits that have since been filed and continue to be filed against Xarelto makers, Bayer and Johnson & Johnson, due to people who have experienced these negative side effects. -
Xarelto Lawsuit Alleges Blood Thinner Caused Ischemic Stroke
Dec 18, 2015 | Top Class Actions
By Robert J. Boumis
A Xarelto lawsuit out of Florida has alleged that a man suffered from an ischemic stroke after taking Xarelto. -
Xarelto liver damage: another life-threatening side effect
Dec 18, 2015 | Xarelto Lawsuit Information
Xarelto (rivaroxaban), is a new blood-thinner medication of the Novel Oral Anticoagulants category (NOACs), manufactured by Bayer AG and Johnson & Johnson. It’s used to treat several conditions such as atrial fibrillation, pulmonary embolism, and deep vein thrombosis. However, Xarelto is also an high-risk medication that has been deemed responsible for several patient’s deaths and many other serious injuries.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
-
Xarelto Lawsuit Alleges Drug Caused Fatal Bleed And Death Of Grandmother
Dec 11, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against blood thinner Xarelto and manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). This particular lawsuit was filed by a granddaughter on behalf of her grandmother who passed away while using Xarelto. She was prescribed the drug in September 0f 2014 in order to treat her deep vein thrombosis condition. Just two months later, she suffered from an intracranial bleed. The bleed quickly became what the plaintiff refers to as “irreversible and fatal,” and the grandmother ultimately passed away on November 14th of 2014, just two months after starting to use the blood thinner.
Details of the lawsuit allege that Xarelto caused the grandmother’s life-threatening bleed as well as significant pain and mental anguish, and tremendous medical expenses. The granddaughter notes within her suit that she and her grandmother saw multiple Bayer advertisements, which seem to promote the drug without indicating that it can cause an increased risk of serious bleeding events, both internal and external. Additionally, she states that she feels that the manufacturer neglected to warn both consumers and doctors about the drug’s lack of antidote and the serious implications that this can cause patients.
Her case was filed in the United States District Court for the Eastern District of Louisiana under number 2:15-cv-05874. In a statement found within the complaint, the plaintiff states that Xarelto marketing also “overstated the efficacy of Xarelto with respect to preventing stroke and systemic embolism.”
The lawsuits surrounding Xarelto, which now number over 2,200 federal cases, have been consolidated to form multidistrict litigation number 2592. They are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. All cases commonly allege the same things that this plaintiff is saying, and many call Xarelto the most dangerous blood thinner currently on the market due to its lack of antidote.
The lack of antidote is an issue of major health concern. It can mean the difference between life and death for bleeding patients. If someone with Xarelto in their system begins to bleed, physicians have no available antidote and therefore will be unable to get their blood to clot. In these instances, the doctors must resort to extreme life-saving measures such as surgery or blood transfusions. When a patient is using a traditional blood thinner, however, such as warfarin, and they begin to bleed, there is an available antidote in vitamin K. Physicians can treat these patients with vitamin K and it will reverse the effects of the drug and help their blood to clot.
As these cases all await trial, Attorney Joseph Osborne is working to ensure that anyone else who may have suffered adverse health effects after taking Xarelto will have the option of looking into their legal rights. It is believed that these individuals may be entitled to substantial compensation. Attorney Osborne is offering free legal consultations for those involved at this time.
To request more information or ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.cbs19.tv/story/30729228/xarelto-lawsuit-alleges-drug-caused-fatal-bleed-and-death-of-grandmother
-
Xarelto Lawsuit Plaintiff From NJ Alleges Drug Cause Severe And Permanent Injuries
Dec 12, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a new lawsuit filed by a man from New Jersey alleging that Janssen Pharmaceuticals (a division of Johnson & Johnson) neglected to properly warn consumers about the severe health risks and dangerous side effects associated with its blood-thinning drug Xarelto. The lawsuit was filed on November 23rd of 2015 in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06264.
Lawsuits federally filed against the drug, which now number over 1,800, have been consolidated to form multidistrict litigation in Louisiana. They will be overseen by Judge Eldon Fallon and involve defendants Janssen and Bayer AG. The cases involved in the MDL all similarly allege that the drug can cause serious uncontrollable bleeding episodes, and that manufacturers were negligent in releasing it to the market without a corresponding antidote to treat bleeding patients in emergency situations.
Having no antidote means that if someone with Xarelto in their system becomes injured and bleeds, physicians will be unable to stop the bleed by clotting that person’s blood. In these instances, doctors must resort to extreme life-saving measures such as surgeries and blood transfusions. Patients who use traditional blood thinners do not have this dangerous issue, as traditional blood thinners have an available antidote in vitamin K. Patients taking traditional blood thinners who become injured and bleed can be treated with vitamin K which will reverse the effects of the blood thinner and allow their blood to clot.
The plaintiff in this particular complaint alleged that after about six months of using Xarelto, he developed life-threatening gastrointestinal bleeding. Due to this bleed, the plaintiff alleges that he suffered severe and permanent injuries, as well as emotional distress, significant medical expenses, and loss of earnings due to time away from work.
His case mirrors many others involved in the Xarelto MDL. Additionally, there is another consolidated grouping of around 500 Xarelto lawsuits which have formed a mass tort in Philadelphia, PA. The plaintiffs in all of these cases share similar stories, some which proved fatal, but all of which have left lasting effects.
As the Xarelto lawsuits await trial, Attorney Joseph Osborne is working to make sure that everyone negatively affected by the drug will have the opportunity to explore their legal rights as well. These individuals may be entitled to substantial compensation. Attorney Osborne is offering anyone who used Xarelto and suffered adverse health effects that they attribute to the drug a free legal consultation.
To ask questions or obtain additional information on Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.abcnews4.com/story/30730651/xarelto-lawsuit-plaintiff-from-nj-alleges-drug-cause-severe-and-permanent-injuries
-
Xarelto Lawsuit Plaintiffs From Nebraska Allege Drug Caused Severe And Permanent Side Effects
Dec 15, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinner Xarelto and manufacturer Janssen Pharmaceuticals, (a division of Johnson & Johnson). The plaintiffs in this case are a couple from Nebraska who allege that the manufacturer marketed an unsafe drug which caused the husband severe and permanent side effects including bleeding and shortened life expectancy.
Details found within the complaint, which has been filed in the U.S. District Court for the Eastern District of Louisiana under case number 2:15-cv-06514, indicate that the husband used Xarelto from May of 2013 through December of 2013, when he suddenly suffered from a gastrointestinal bleed which the couple alleges was caused by the drug. A gastrointestinal bleed or gastrointestinal hemorrhage can include bleeding anywhere along the GI tract, from the mouth to the rectum.
Xarelto has been the subject of a recent surge of lawsuits all similarly alleging that the drug can cause uncontrollable bleeding episodes. Federally, these lawsuits have been consolidated to form multidistrict litigation number 2592, and they include over 2,200 cases. The cases are being overseen in the Eastern District of Louisiana by Judge Eldon Fallon.
One of the biggest problems that Xarelto lawsuit plaintiffs discuss is the drug’s lack of antidote. If someone using Xarelto becomes injured and bleeds, physicians will be unable to do anything to counter the effects of the drug and get this person’s blood to clot. Traditional blood thinners are different in this way. They offer an antidote in vitamin K. If someone taking a traditional blood thinner is injured and bleeding, physicians can treat them with vitamin K which will counter the drug’s effects and allow that person’s blood to clot. Because Xarelto doesn’t have this ability, doctors have to resort to extreme life-saving measures when a patient on Xarelto is bleeding, such as surgery or blood transfusions. The lack of antidote poses a significant risk that these patients can bleed out.
In this particular case, the plaintiffs are seeking compensatory and punitive damages as well as money to cover litigation costs. As this case and many others await trial, Attorney Joseph Osborne is working to ensure that everyone negatively affected by Xarelto will have the opportunity to explore their legal rights. It is believed that these individuals may be entitled to substantial compensation. Attorney Osborne is providing free legal consultations for those involved at this time.
To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wave3.com/story/30757313/xarelto-lawsuit-plaintiffs-from-nebraska-allege-drug-caused-severe-and-permanent-side-effects
-
Xarelto Wrongful Death Lawsuit Filed In South Florida Sues For Uncontrollable Fatal Bleeding
Dec 16, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a new lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) claiming wrongful death. The suit was filed in south Florida and claims that Xarelto manufacturers failed to properly warn consumers of the significant dangers associated with their blood-thinning drug. The plaintiff alleges that the drug caused her husband to die after suffering an episode of uncontrollable internal bleeding.
The U.S. Food and Drug Administration approved Xarelto in 2011, and it launched onto the market as a revolutionary new type of blood thinner. While traditional blood thinners required regular monitoring and special diets, Xarelto did not. These benefits perhaps helped consumers to ignore one fact that plaintiffs bring up regularly today: the drug was released to the market with no corresponding antidote.
A blood thinner without an antidote simply means that when a patient using the drug bleeds, there is no way to clot their blood. In these situations, physicians must resort to extreme life saving measures such as blood transfusions or surgery in an attempt to keep the patient alive, and even then, the chances of death are significant.
Traditional blood thinners–those that required a special diet like Warfarin, did so because they have an available antidote in vitamin K. This means that if a patient using a traditional blood thinner begins to bleed, physicians can administer vitamin K which will counter the effects of the drug and allow their blood to clot, potentially saving their life.
Today, Xarelto has become the topic of over 2,200 federal lawsuits and another 500 suits which have been consolidated separately in a Philadelphia, Pennsylvania mass tort group. The lawsuit for this specific widow was filed in the U.S. District Court for the Southern District of Florida under case number 9:14-cv-80831 before being transferred to the Eastern District of Louisiana during multidistrict litigation consolidation. It has become a part of MDL number 2592, and is being overseen by the Honorable Judge Eldon Fallon.
Details within the woman’s lawsuit state that her husband was using Xarelto to treat his atrial fibrillation. While using the drug, he suffered from a subdural hemorrhage (brain bleed) and passed away when physicians could not stop the bleed with active Xarelto in his system.
As this case and so many others await trial, plaintiffs anticipate that other lawsuits against Xarelto manufacturers will continue to be filed. During this time, Attorney Joseph Osborne is working to help ensure that everyone who has been negatively affected by the drug will have the opportunity to evaluate their legal rights. These individuals and their families may be entitled to compensation. Attorney Osborne is offering complimentary consultations for involved parties at this time.
To request more information on Xarelto lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.kltv.com/story/30768827/xarelto-wrongful-death-lawsuit-filed-in-south-florida-sues-for-uncontrollable-fatal-bleeding
-
Lawsuitsettlementnews.com Secures Large Capital for Xarelto and Pradaxa Funding
Dec 16, 2015 | LawsuitSettlements.com
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they have secured large capital for Xarelto and Pradaxa funding. They are also reporting that they are able to provide assistance for Xarelto and Pradaxa bleeding victims, or their loved ones, who are in need of an attorney. Pradaxa and Xarelto are both blood thinners and targets of thousands of lawsuit claims, with similar allegations of uncontrollable and sometimes fatal bleeding events. While Pradaxa maker, Boehringer Ingelheim, reached a $650MM settlement on approximately 4,000 cases filed in state and federal courts, the Xarelto cases have not been settled. The first bellwether trials in the Xarelto multidistrict litigation are set to take place starting in February of 2017.
The Pradaxa settlement value was approximately $160K average per case, and plaintiff attorneys close to the litigation believe that Xarelto cases could see similar settlement amounts if the plaintiffs can prove their cases in a court of law. Xarelto's maker, Bayer and Johnson & Johnson's Janssen Pharmaceutical Division, continues to fight the suits. MTS encourages anyone who is looking for lawsuit funding on their Xarelto or Pradaxa case, or anyone looking for assistance with finding a Xarelto or Pradaxa law firm or lawyer, to contact the company immediately for assistance. MTS has secured large capital for Xarelto and Pradaxa funding as there have been thousands of victims affected by these blood thinners. If you, or a loved one, need assistance, please visit the company's website athttp://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases for more information.
Chris Janish, CEO of MTS, commented on the recent announcement, "We have been receiving many calls from patients who have had themselves or family members hospitalized for uncontrollable bleeding events while taking the blood thinner Xarelto. We have been able to connect them with what we believe are the best Xarelto law firms in the country to help file their claims. Additionally, both Pradaxa settlement funding and Xarelto pre-settlement funding applications have been on the rise of late as both litigations have been in the news in recent months."
MTS is prepared to help those who need lawsuit help with finding a qualified Xarelto law firm or Xarelto lawyer to provide a free evaluation on their specific bleeding case. To learn more about MTS' services involving Xarelto, Pradaxa, or other litigations, please visit: http://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can help you. Victims of Pradaxa or Xarelto usage and complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit:http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have been injured by Xarelto or Pradaxa and need lawsuit money or lawsuit help, including finding a Xarelto or Pradaxa law firm, and would like to speak with a live agent who can answer any questions you may have, please call: 877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.comand an agent will contact you shortly.
Disclaimer: MT Services LLC, operato
-
Xarelto Lawsuit Alleges Studies On Blood Thinner Were Not Reliable Or Properly Managed
Dec 17, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.comreports on a lawsuit filed against the manufacturers of blood-thinning drug Xarelto, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The lawsuit alleges that the companies neglected to properly warn consumers of the significant bleeding issues associated with their drug, and also that the studies that medical journals and advertisements relied on were unreliable and improperly managed. The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana under number 2:15-cv-04273.
Upon its initial market release, Xarelto was considered a revolutionary new type of blood thinner. Unlike warfarin, which has been around for decades, it promised no blood or diet monitoring. Plaintiffs involved in lawsuits against the drug today, however, are no longer focused on these benefits. A glaring negative is what they instead see: Xarelto has no available antidote. So while the effects of warfarin can be quickly reversed by applying vitamin K to someone who is bleeding, the effects of Xarelto cannot. This could be the difference between life and death for those with internal or external bleeding episodes.
Patients who use Xarelto and begin to bleed are at risk for uncontrollable bleeding. To treat individuals in these circumstances, physicians have to resort to extreme life saving measures such as blood transfusions, or surgery to remove pressure and pooling blood. In court documents, plaintiffs have stated: “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects.”
Generally, consumers are prescribed Xarelto to treat atrial fibrillation, pulmonary embolism, or deep vein thrombosis. The drug can also be given to those who have undergone recent hip or knee replacement surgeries. In these patients, it is intended to help prevent the risk blood clots and stroke. It has been noted that in medical journals across the country, Xarelto is the most widely advertised drug. These journals are meant to keep the medical community aware of current medical trends and advancements.
The plaintiffs in this particular case accuse the defendants of focusing only on the positive aspects of the drug in both advertisements and studies noted to the public. What they conceal, these plaintiffs allege, is the great dangers the drug poses, including death by bleeding out. Several plaintiffs involved in the currently consolidated Xarelto lawsuits are representing individuals who have died from severe bleeding episodes while taking the drug. In this complaint, plaintiffs make note that throughout both the U.S. and Germany, there have been thousands of “adverse events” reported which are linked to Xarelto use.
The Xarelto bleeding lawsuit cases now number over 2,200 in federal court. They have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation in MDL number 2592, and are being overseen in the Eastern District of Louisiana by the Honorable Judge Eldon Fallon. As these lawsuits await trial preparations, they are expected to continue to grow in number.
Attorney Joseph Osborne is working to ensure that everyone negatively affected by Xarelto will have the opportunity to explore their legal rights. These individuals may be entitled to significant compensation. Patients who have used Xarelto and subsequently suffered from adverse health effects are being offered complimentary legal consultations at this time.
To ask questions or request more information on this topic, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wdrb.com/story/30782458/xarelto-lawsuit-alleges-studies-on-blood-thinner-were-not-reliable-or-properly-managed
-
Xarelto Lawsuit Plaintiff Alleges That Manufacturers' Negligence Caused Husband's Death
Dec 18, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed which details the dangerous side effects associated with anticoagulant Xarelto. This lawsuit now joins with others consolidated in MDL number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. The MDL is being overseen in the U.S. District Court for the Eastern District of Louisiana by the Honorable Judge Eldon Fallon.
This complaint was filed by a widow in Missouri who alleges that the negligence of Janssen Research, parent company Johnson & Johnson, and Bayer Healthcare ultimately caused the wrongful death of her husband.
Court documents show that the woman’s husband was prescribed Xarelto by his primary care doctor in December of 2012. He used the drug until he was admitted to an intensive care unit in a local hospital on May 4th of 2013. Upon his admission, the hospital staff took him off of the drug, but were unable to successfully flush it from his system before he died of an intracerebral hemorrhage caused by a bleed in his brain tissue.
As many plaintiffs who have filed lawsuits against Xarelto state, if she and her husband had been better made aware of the dangers of the drug, they would have chosen a safer alternative. She also states that the defendants did not properly warn consumers or the medical community about the dangers of Xarelto’s side effects and even purposefully hid information concerning the drug’s risks from the public.
Across the nation, Xarelto lawsuits continue to be filed. In federal court, the cases have soared over 2,200, and these are joined by a mass tort group in Philadelphia, Pennsylvania of around 500 other cases. Plaintiffs involved in these cases all share similar allegations concerning the blood thinner, which, to date, has no available antidote.
Attorney Joseph Osborne is working to ensure that as these cases await trial preparations, everyone who has experienced adverse health effects after using Xarelto will have the option of looking into their legal rights. To help accomplish this, he is offering free legal consultations to involved individuals. It is believed that these people and their families may be entitled to substantial compensation.
To ask questions or request more information, please contact Attorney Osborne by calling (866) 425-8902.
http://www.12newsnow.com/story/30782570/xarelto-lawsuit-plaintiff-alleges-that-manufacturers-negligence-caused-husbands-death
-
Xarelto Lawsuit Alleges Life-Threatening Severe Bleeding Event
Dec 11, 2015 | Top Class Actions
By Laura Schultz
A Xarelto lawsuit claims that after five-months of use, the drug caused an Ohio man to suffer from a life-threatening rectal bleed.
Plaintiff Johnny B. filed the Xarelto lawsuitagainst Janssen Research & Development and Bayer Pharmaceuticals. Janssen Research & Development is formally known as Johnson & Johnson Pharmaceuticals and Research.
According to the Xarelto lawsuit, Johnny began using Xarelto in January 2013 in order to reduce his risk of suffering from pulmonary embolisms. After taking the medication for approximately 5 months, Johnny stopped taking Xarelto when he began to allegedly experience life-threatening rectal bleeding.
The plaintiff claims that Xarelto manufacturers failed to warn the medical community and general public about serious risks associated with taking the blood thinner. The Xarelto lawsuit also alleges that the defendants concealed their knowledge of Xarelto side effects from the plaintiff and the general public.
According to the Xarelto allegations, Johnny experienced severe and permanent injuries along with ongoing pain and emotional distress. Johnny further asserts claims of negligence, strict products liability, breach of warranty, fraudulent misrepresentation, fraud and deceit.
Johnny is seeking compensatory damages for his injuries and pain and suffering, attorneys fees, reimbursement for the cost of the proceedings, and other compensation as the court sees fit.
What is Xarelto?
Xarelto is a popular new blood thinning medication on the market. It is primarily used to reduce the risk of stroke and systemic embolisms in patients with atrial fibrillation, and to reduce the risk of clotting in patients who have undergone knee or hip replacement surgery.
Xarelto was FDA approved for consumer use in 2011. It is one drug in a whole generation of new anticoagulant medications that transformed how patients live with clotting risks.
Prior to these medications entering the market, many patients were prescribed Warfarin, also known as Coumadin, to reduce clotting risks. Patients taking Warfarin are required to undergo a strict diet and must have regular blood monitoring to ensure they are taking the proper dosage.
Xarelto and many of the new drugs on the market do not share these requirements and are given to patients in set doses. Unfortunately when these new blood thinning medications entered the market they had no known antidote unlike Warfarin.
Patients who take Warfarin and suffer uncontrolled bleeding can be given a dose of vitamin K mixed with fresh or frozen plasma in order to reduce the anticoagulant effects of the medication.
FDA adverse event reports suggest that blood thinning medications are some of the most dangerous on the market. The adverse event reports suggest that many patients have suffered from uncontrolled bleeding and other serious side effects.
Xarelto Bleeding Lawsuits
Several Xarelto lawsuits have been filed in federal courts across the United States. Product liability attorneys are currently looking for new potential plaintiffs to bring Xarelto lawsuits.
A Xarelto lawyer can help weigh a potential plaintiffs facts and assist in determining whether or not a Xarelto lawsuit should be brought. Successful plaintiffs may receive signification compensation for their injuries.
The Xarelto Lawsuit is Case No. 2:15-cv-01149-EEF-MBN and MDL No. 2592 in the U.S. District Court in the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/234765-xarelto-lawsuit-alleges-life-threatening-rectal-bleed/
-
Six Years for Troubled Xarelto v. Six Decades for Reliable Coumadin
Dec 14, 2015 | LawyersandSettlements.com
By Gordon Gibb
As we are about a month away from the selection of four bellwether Xarelto trials that are scheduled for early 2017, it’s instructive to compare the rocky road of Xarelto with the longevity of Coumadin (warfarin). The latter had been the gold standard for blood thinning well before the introduction of Xarelto and, before that, Pradaxa. In the short tenure of Xarelto as the currently leading anticoagulant, more than 1,700 plaintiffs have reported a Xarelto Bleeding Issue.
That’s a problem, because unlike Coumadin, when a Xarelto Bleedout issue occurs, there is no de facto antidote to stop it.
Warfarin has been around since the late 1940s, and was originally introduced as an effective poison against rats and mice. The references to the parallels between rat poison and blood thinning in humans over the years have been legion; however, the fact remains that warfarin, as Coumadin, has proven effective as a blood thinner since 1954.
Akin to Xarelto Side Effects, or the adverse reactions found with any and every medication ever designed, Coumadin has not been without its shortcomings. Blood and diet have to be strictly monitored in order to keep the thinning properties of warfarin in balance. The consumption of leafy greens, for example, carries the potential for weakening the blood-thinning properties of warfarin given generous amounts of vitamin K commonly found in such foods.
However, therein lay the secret weapon for reversing a bleeding event were one to occur in a patient on Coumadin: a fresh injection of vitamin K. While not a magic bullet, vitamin K provided a physician with an implement in his tool belt to deal with a bleeding issue, which, left unchecked, could result in a serious health issue - and possibly death.
With a Xarelto Bleedout, there is no such de facto standard, or antidote for reversing such an event - a fact the US Food and Drug Administration (FDA) acknowledges in a summary view of Xarelto dated January 2014:
“Reversal of Anticoagulant Effect: A specific antidote for rivaroxaban [Xarelto] is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable [see Clinical Pharmacology (12.3)]. Protamine sulfate and vitamin K are not expected…The use of other procoagulant reversal agents like activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (rFVIIa) has not been evaluated.”
While an antidote is being developed, it is not yet ready for implementation, or so it is reported. In the meantime, Xarelto has quickly risen to the top in the anticoagulant world.
It hasn’t taken that long, given that Xarelto was approved on July 1, 2011 for the prevention of deep vein thrombosis (blood clots) in patients undergoing knee or hip replacement surgery (a huge sector of the patient population). The FDA expanded the indications for Xarelto just a few months later, in November 2011, for the prevention of stroke in patients with atrial fibrillation. A year later, on November 2, 2012, the FDA gave Bayer AG and Janssen yet another early Christmas present - approval to expand the use of Xarelto for the treatment, reduction or recurrence of blood clots.
Xarelto - as many a Xarelto lawsuit alleges - was introduced to great fanfare as an alternative to Coumadin. The latter, as noted above, required constant monitoring of blood and diet to remain safe and effective. The time and effort to undertake and maintain such monitoring have left physicians and patients alike pining for an alternative that was equally safe and effective, with less effort. Pradaxa emerged as the first real alternative to warfarin since Coumadin was approved for blood thinning in 1954.
Xarelto soon followed, and was hailed as a safe and effective alternative to Coumadin without the same degree of intensive monitoring that has been the bastion, and the bane, of warfarin.
In the four years since Xarelto came on the market, rivaroxaban has since risen to the very top of the blood thinner category. And by September 2015, there were no fewer than 1,710 lawsuits alleging Xarelto Bleeding complications or even Xarelto Death, consolidated by the Judicial Panel Multidistrict Litigation in the Eastern District of Louisiana.The lawsuits keep coming, with plaintiffs alleging they were not aware that a Xarelto Bleedout could not be stemmed in the same fashion as that which is available for Coumadin. What’s more, plaintiffs are now claiming that Bayer AG and Janssen were wrong to suggest that rivaroxaban did not require the kind of stringent monitoring associated with Coumadin - and - given the lack of a de facto method to reverse Xarelto Bleeding complications - monitoring should indeed be required. To suggest otherwise, it is alleged, would be and is completely irresponsible.
All eyes will be focused on January 2017, when the first of four bellwether Xarelto trials is set to begin. Who knows how many Xarelto lawsuits will have been filed and enveloped in multidistrict litigation by then.
By then, Xarelto would be entering its sixth full year as an approved anticoagulant in the United States.
At the same time, Coumadin will be well into its sixth full decade - quietly chugging along since 1954 with an antidote and the need for strict monitoring that pundits and plaintiffs say Xarelto should have required all along…https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-31-21120.html#.Vm8RLkorK00
-
Several Claims Added to Xarelto MDL
Dec 12, 2015 | Drug Reporter
By Stephanie Reid
On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known rivaroxaban, is a relatively new blood thinning drug touted to offer patients an increased level of convenience as they treat their underlying medical conditions.
More specifically, the makers of Xarelto market the drug in direct competition with the traditional blood thinner warfarin – highlighting the decreased need for time-intensive trips to the blood clinic. However, patients across the U.S. are asserting that Xarelto carries an increased risk of unstoppable bleeds, and is not responsive to coagulation antidotes characteristic of warfarin.
Moreover, Xarelto plaintiffs contend that the makers of the drug – a group including Janssen Pharmaceuticals and Bayer Health – knew or should have known of its dangers, and failed to warn patients accordingly.Details of Xarelto lawsuit
The recent complaint was filed by five plaintiffs – all of whom claim some degree of injury directly caused by the use of Xarelto – along with a sixth plaintiff suing on behalf of the estate of one allegedly killed as a result of hemorrhaging caused by Xarelto.
According to the details of the complaint, the plaintiffs suffered from issues including gastrointestinal bleeds, intracranial hemorrhaging, and intracerebral hemorrhaging. The plaintiffs, on average, took Xarelto for approximately 5 months before the onset of internal bleeding. One plaintiff, however, was prescribed the drug for a matter of days before experiencing a sudden life-threatening hemorrhage.
Causes of action
For the five plaintiffs suing on the own behalf, each raises several counts of negligence and product liability against the defendants. Specific to the negligence count, the plaintiffs assert that the defendants acted unreasonably dangerous in the marketing, design, production, and manufacture of Xarelto – and should have taken much greater precautions when promoting such a dangerous product to consumers. Further, the plaintiffs contend that the defendants failed to adequately test the product on its targeted patient demographic, which is primarily patients suffering from pulmonary embolism and deep-vein thrombosis (DVT) – a condition that can cause fatal blood clots.
The plaintiffs also contend that the defendants knew about the dangers of Xarelto, yet continued to spend millions of dollars marketing the drug to consumers nonetheless. In their strict products liability count, the plaintiffs categorized Xarelto as “unsafe, defective, and inherently dangerous” in its current form.
The Xarelto lawsuit continues with several more counts, including breach of express and implied warranties, fraudulent misrepresentation and concealment, negligent misrepresentation, fraud and deceit and violations of state consumer protection statutes.
Lastly, the estate of the deceased plaintiff filed a wrongful death claim, along with a survival action to compensate survivors for the pain and suffering associated with the sudden death of their loved one.
Background of Xarelto
Xarelto was approved by the Food and Drug Administration (FDA) in July, 2011 for the treatment of hip and knee replacement patients who were at an increased risk for blood clot and/or deep-vein thrombosis. In November of that year, the drug was awarded a broader approval for the treatment of patients with non-valvular atrial fibrillation at an increased risk for stroke or systemic embolism. From there, the drug makers spent tens of millions of dollars advertising in medical journals and on-air television advertisements, resulting in global sales topping $2 billion.
In June, 2013, the makers of Xarelto received warning from the FDA that their advertisements were “false or misleading.” As well, the FDA reported hundreds of adverse events related to Xarelto use in its first year on the market.
http://drugreporter.com/2015/12/several-claims-added-xarelto-mdl/
-
Xarelto MDL: Drug Makers Attempt Geographic Limitations
Dec 14, 2015 | Top Class Actions
By Amanda Antell
Pharmaceutical giants Bayer and Janssen have been accused of trying to undermine the Xarelto bellwether litigation process by limiting early trial candidates to only a handful of states.
The plaintiff group has recently accused the drug manufacturers of proposing a “truly unprecedented” idea, which would restrict the bellwether selections to Louisiana, Mississippi, and Texas.
While the companies agree that the Xarelto bleeding lawsuits should be categorized, both parties argue over the geographical locations of the districts each case is filed in. As of now the companies disagree with the lawsuits chosen going before juries, because they are from different districts then from where the companies’ headquarters are located.
According to the proposal from Bayer and Janssen, the companies name a specific amount of Xarelto lawsuits per designated state. More specifically the companies are calling for half of the bellwether trials to come from Louisiana, six from Mississippi, two from Texas, and 12 from other states.
Half of the specific geographic districts cases would be selected at random, with each competing party selecting a quarter of those cases that are also based on geographical location.
The plaintiffs responded by stating that the companies were impairing the selection process of the cases, and are basically “cherry picking” which Xarelto lawsuits they want.
The companies countered in a separate filing that their proposal would adhere to the multidistrict litigation (MDL) as envisioned by the presiding judge, U.S. District Judge Eldon Fallon of the Eastern District of Louisiana.
Xarelto Bellwether Trial Status
In a previous proposal from the plaintiffs, they are requesting the Court to conduct a census of claims first so they can be sorted into categories that are representative of typical Xarelto injury cases.
Then the plaintiffs and defendants would then select their respective Xarelto injury claims based on said categories, with at least two of their 10 cases coming from the Eastern District of Louisiana.
Judge Fallon had previously ordered the parties to propose a selection process for the pool of 40 bellwether Xarelto lawsuits, as part of the coordinated pretrial proceedings. Each of the selected cases will go through a specific discovery process, to prepare for a series of early trial dates that are expected to begin with Aug. 01, 2016.
Xarelto Bleeding Allegations
Xarelto is a popularly prescribed anticoagulant manufactured jointly between Bayer and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, and is meant to be a direct competitor against other new generation anticoagulants and Warfarin. The blood thinner is used to prevent strokes in patients who undergo hip or knee replacement surgery as well as treat or reduce the recurrence of deep vein thrombosis and pulmonary embolism.
Unfortunately Xarelto and other new generation anticoagulants have been accused of causing internal bleeding injuries, including life-threatening gastrointestinal bleeding, hemmorhagic strokes, and brain hemorrhages.
Many injured patients have filed Xarelto lawsuits alleging the drug manufacturers ailing to warn consumers that Xarelto does not have an antidote, leaving doctors without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding.
Ever since the Xarelto MDL was established in December 2014 the number of cases filed has grown dramatically. Six months after its establishment, in June 2015, there were approximately 500 lawsuits filed in the MDL. Court documents show that currently there are about 1,200 lawsuits filed in the MDL and that number is expected to continually rise as litigation continues.
The Xarelto MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/247248-xarelto-mdl-drug-makers-attempt-geographic-limitations/
-
Xarelto Internal Bleeding Injuries Lawsuit Filed In Mississippi
Dec 15, 2015 | BloodThinnerHelp.com
By Joseph Osborne
Xarelto is a highly popular blood thinner drug that has seen over 11 million scripts written in all of America. Xarelto is prescribed in order to avert blood clots forming that can lead to severe strokes. However, Xarelto has been closely examined by the medical community in an effort to determine theside effects this anticoagulant could have. The research conducted over Xarelto usage has associated the drug to serious side effects like uncontrollable internal bleeding. There have already beenlawsuits that have since been filed and continue to be filed against Xarelto makers, Bayer and Johnson & Johnson, due to people who have experienced these negative side effects.
What You Need To Know About Using Xarelto
The Food and Drug Administration (FDA) first approved Xarelto in 2011. Xarelto was approved to prevent blood clots and DVT in individuals who have undergone hip and knee replacements, as well for the overall use of lowering the chances of blood clots forming again.
How Xarelto works is by being an Xa inhibitor, which means it blocks thrombin. Thrombin is the chemical in the blood that is responsible for blood clotting. Thrombin restriction permits clots breakdown to take place and stops clots and deep vein thrombosis (DVT), that as mentioned above, can happen when a person has a hip or knee replacement procedure or is being treated for Atrial Fibrillation (AFib).
The common concern with anyone taking blood thinners is that if there is an unfortunate incident that requires the blood to clot again, it maybe hard to stop the bleeding. In worst case scenarios the bleeding can end up causing pools of blood to surround the vital organs. Furthermore, the bleeding can end up stopping blood supply to vital organs which could lead to fatal results.
One would think that most blood thinners would have a reversal antidote for just such cases. Well, yes and no. For a blood thinner like Warfarin, yes, the usage of Vitamin K in the body helps the blood clot again and reverses the effects of a blood thinner. With Xarelto, the answer is no. There is no known reversal agent for the effects of Xarelto because Xarelto blocks thrombin which is not easy to reverse. This is quite a serious issue that saw the FDA in 2014, issue a warning related to Xarelto, stating that the FDA knows there is a danger of bleeding in a person using Xarelto and advised that a patient has blood transfusions or blood replacements if there is any sign of blood loss.
Probable Number Of People Affected By Xarelto In Mississippi
The most recent 2014 US Census Bureau records relay that Mississippi’s population is 2,994,179. We used a calculation where we weighed Mississippi’s population opposite the United States’ population. In so doing, we are able to estimate that the probable number of prescriptions out of the 11 million Xarelto scripts, 103,248 people in the United States had scripts written for Xarelto in Mississippi.
In order to work out how many people out of the 103,248 scripts ended up having internal bleeding injuries in Mississippi, we made use of the Rocket AF study as our base for incidence rates from clinical trials. From that we worked out that 1,755 people from Mississippi encountered the negative effects of using Xarelto. We went further to work out the probable number of people affected by Xarelto in Mississippi’s five most densely populated cities. The five city populations are as follows:
Jackson- 171,155 population
Gulfport- 71,750 population
Southaven- 51,824 population
Hattiesburg- 47,016 population
Biloxi- 44,984 population
Mississippi Residents Affected By Xarelto In Its Five Most Densely Populated Cities
Jackson- 100
Gulfport- 42
Southaven- 30
Hattiesburg- 28
Biloxi- 26
Steps Towards Filing A Xarelto Lawsuit
If an internal bleed took place that led to severe injury or in worst case even death, and Xarelto was being used, then there is a strong chance Xarelto was to blame and a lawsuit can be filed.
If upon reading this information and the it sounds true of your case or someone dear to you, then we encourage you to get in contact with us to discuss your case specifics.
All About BloodThinnerHelp.com
This website BloodThinnerHelp.com is funded by several attorneys committed to making sure Xarelto victims seek and get the justice they deserve.
As it is now, multitudes of people have been in touch with us due to serious injuries or loss of a loved one beacause of internal bleeding or a pulmonary embolism among other things brought on by Xarelto usage.
It should be noted however, that our Xarelto advocates are not authorized to practice law in Mississippi. Our advocates are authorized to practice law in Pennsylvania, New Jersey, District of Columbia, Virginia and Massachusetts. Within these states our attorneys can file lawsuits on behalf of families all across America. Families can also opt to work with local Mississippi counsel with the help of our trusted network attorneys who can assist you in filing your case.
Mississippi Hospitals
In cases of emergency due to Xarelto related injuries, it is imperative to seek legal help as soon as possible. Visit some of the following Mississippi hospitals:
North Mississippi Medical Center
830 South Gloster Street
Tupelo, MS 38801-4934(662) 377–3000
Anderson Regional Medical Center
2124 14th Street
Meridian, MS 39301-4040(601) 553–6000
http://bloodthinnerhelp.com/xarelto-internal-bleeding-injuries-lawsuit-in-mississippi/
-
Xarelto Lawsuit Alleges Blood Thinner Caused Ischemic Stroke
Dec 18, 2015 | Top Class Actions
By Robert J. Boumis
A Xarelto lawsuit out of Florida has alleged that a man suffered from an ischemic stroke after taking Xarelto.
This Xarelto ischemic stroke lawsuitalleges that even though Xarelto is promoted as protecting a patient for 24-hours on a single 20 milligram dose, it did not. Xarelto is designed to reduce the risk of stroke, the problem suffered by the plaintiff.
Ischemic strokes happen when when there is an obstruction in a blood vessel that is supposed to supply blood to the brain.
Though most Xarelto lawsuits have focused on Xarelto bleeding, in many ways the opposite of this man’s stroke, concerns have been raised that the one-size-fits-all approach to Xarelto may mean that some patients have too much in their system, possibly leading to Xarelto bleeding, while others, like the plaintiff, may not have enough, leaving them vulnerable to strokes.
His Xarelto lawsuit alleges that despite assurances of Xarelto’s effectiveness and safety, it was not enough to prevent the plaintiff from suffering a life-threatening ischemic stroke.
Xarelto is a blood thinner, or anticoagulant. These drugs are designed to decrease the risk of strokes, by making it harder for blood to clot. Drugmakers promote Xarelto as not requiring blood monitoring to evaluate how well the drug is working. This is used as a selling point over older anticoagulants. However, concerns about the safety of Xarelto have emerged.
The Xarelto lawsuit names the makers of the drug, Jansen Pharmaceuticals and drug icon Bayer as defendants.
Most Xarelto lawsuits allege that sometimes Xarelto works too well and there is no way to quickly fix the situation if it does. All anticoagulants carry the risk of leading to uncontrollable bleeding.
However, with older anticoagulants, antidotes exist, which can effectively turn off the drug if a patient experiences uncontrollable bleeding like gastrointestinal bleeding or pulmonary bleeding.
However, if a patient experiences Xarelto bleeding, there is no known antidote, and doctors must use more general treatments like transfusions and artificial clotting factors to try and reverse it.
Despite hundreds of Xarelto lawsuits, Xarelto and other newer-generation anticoagulants are steadily gaining popularity over older drugs of this type. This has much to do with the alleged benefits of Xarelto.
First, Xarelto supposedly does not require the same regular blood tests as older drugs. Additionally, Xarelto has fewer dietary and drug interactions than older drugs. However, concerns about a lack of an antidote and questions about the efficacy of once-a-day dosing have lead to hundreds of Xarelto lawsuits.
Xarelto lawsuits allege that drugmakers knew that Xarelto was allegedly potentially more dangerous that existing drugs, but marketed it anyway, exposing patients to the risk of alleged Xarelto side-effects like Xarelto bleeding. Xarelto lawsuits typically seek to recoup the cost of medical care and other costs allegedly stemming from Xarelto side-effects.
So many Xarelto lawsuits have been filed that the legal system has resorted to a process called a multidistrict litigation or MDL. In MDLs, similar cases are coordinated together to help streamline the legal process. Since Xarelto lawsuits typically make similar claims, hinge on similar evidence, and seek similar damages, they have been grouped together into a single Xarelto lawsuit MDL.
The Xarelto Lawsuit MDL MDL is In RE: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the United States District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/258852-xarelto-lawsuit-alleges-stroke/
-
Xarelto liver damage: another life-threatening side effect
Dec 18, 2015 | Xarelto Lawsuit Information
Xarelto (rivaroxaban), is a new blood-thinner medication of the Novel Oral Anticoagulants category (NOACs), manufactured by Bayer AG and Johnson & Johnson. It’s used to treat several conditions such as atrial fibrillation, pulmonary embolism, and deep vein thrombosis. However, Xarelto is also an high-risk medication that has been deemed responsible for several patient’s deaths and many other serious injuries.Hundreds of lawsuits were filed against the pharmaceutical companies that manufacture this drug, as many people suffered uncontrollable internal bleeding that doctors had no way to stop even after hospitalization. Differently from other similar drugs such as Warfarin in fact, there’s no known antidote to reverse Xarelto effects, so once a life-threatening bleeding event occurs, the patient is at risk for severe injuries and even death.However, several other possible potentially fatal or severe Xarelto side effects are still under current post-marketing investigation since this drug hit the worldwide market in 2008. Among these, one of the most alarming Xarelto adverse reaction is the risk of liver damage or liver failure associated with this drug. Xarelto liver damage has been investigated as a possible risk for people under Xarelto medication, and several cases Xarelto-induced liver injury have been reported, including several acute liver failure (ALF) events [1]. A recent analysis of the results coming from three large international pharmacovigilance databases revealed a significant number of hepatic adverse reactions where Xarelto was reported as a suspected cause.
Can Xarelto damage your liver?
Other than internal hemorrhage and gastrointestinal bleeding, the most reported side effects of Xarelto is liver damage, which can be spotted by elevated liver enzymes ALT and AST in blood tests [3]. Results from the 4 RECORD (Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of Deep Venous Thrombosis and Pulmonary Embolism) studies, showed that 2.33% of the 6183 patients treated with rivaroxaban had increased transaminase (liver enzymes) levels more than 3 times higher than the upper limit of normal (ULN) [4]. Other two additional cases of patients showing symptoms of a liver injury after treatment with Xarelto, were recently published in the Journal of the American Medical Association, further confirming an alarming possible hepatotoxicity of this drug [5].
It should also be noted that over two-thirds of the orally administered drug is eliminated via bile or urine after hepatic metabolism [6]. If the liver function is compromised, it is theoretically possible that the blood levels of this drug could increase because liver is not able to eliminate a sufficient amount of Xarelto from the body. However the main selling points of this medication, were its purported safety and the fact that no blood monitoring was required, as they were widely advertised through television and internet. The lack of blood monitoring means that patients cannot be aware if the drug effects have increased to the point of becoming dangerous in terms of increased risk of bleeding accidents, and an appropriate dosage adjustment is thus required.
As treatment with Xarelto can thus be associated with severe, symptomatic liver damage and consequent bleeding risks, both patients and physicians should be fully informed of this significant danger. A warning regarding symptomatic liver damage should be included in the drug label. Otherwise, patients suffering liver injury as side effects of Xarelto do have all the rights to file a lawsuit against its manufacturers for providing misleading information.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
Add recipients
Suggested